Progress and prospects for L2-based human papillomavirus vaccines

Rosie T. Jiang, Christina Schellenbacher, Bryce Chackerian, Richard B.S. Roden

Research output: Contribution to journalReview article

Abstract

ABSTRACT: Human papillomavirus (HPV) is a worldwide public health problem, particularly in resource-limited countries. Fifteen high-risk genital HPV types are sexually transmitted and cause 5% of all cancers worldwide, primarily cervical, anogenital and oropharyngeal carcinomas. Skin HPV types are generally associated with benign disease, but a subset is linked to non-melanoma skin cancer. Licensed HPV vaccines based on virus-like particles (VLPs) derived from L1 major capsid antigen of key high risk HPVs are effective at preventing these infections but do not cover cutaneous types and are not therapeutic. Vaccines targeting L2 minor capsid antigen, some using capsid display, adjuvant and fusions with early HPV antigens or Toll-like receptor agonists, are in development to fill these gaps. Progress and challenges with L2-based vaccines are summarized.

Original languageEnglish (US)
Pages (from-to)853-862
Number of pages10
JournalExpert review of vaccines
Volume15
Issue number7
DOIs
StatePublished - Jul 2 2016

Keywords

  • L2
  • adjuvant
  • anogenital cancer
  • capsid display
  • cervical cancer
  • human papillomavirus
  • multimer
  • non-melanoma skin cancer
  • oropharyngeal cancer
  • toll-like receptor agonist

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Progress and prospects for L2-based human papillomavirus vaccines'. Together they form a unique fingerprint.

  • Cite this